Is Halozyme Therapeutics stock close to its 52-week high?
According to the current price, Halozyme Therapeutics is 98.39% away from the 52-week high. What are analysts forecasts for Halozyme Therapeutics stock? The 11 analysts offering price forecasts for Halozyme Therapeutics have a median target of 48.09, with a high estimate of 60.00 and a low estimate of 26.00.
How much is a halo stock worth?
One share of HALO stock can currently be purchased for approximately $33.89. How much money does Halozyme Therapeutics make? Halozyme Therapeutics has a market capitalization of $4.77 billion and generates $267.59 million in revenue each year.
What are Wall Street's price targets for Halozyme Therapeutics'stock?
6 Wall Street analysts have issued 1 year price objectives for Halozyme Therapeutics' stock. Their forecasts range from $48.00 to $65.00. On average, they expect Halozyme Therapeutics' share price to reach $54.60 in the next year.
How do I contact Halozyme?
The biopharmaceutical company can be reached via phone at 858-794-8889, via email at [email protected], or via fax at 858-704-8311. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks.
What is Halozyme Therapeutics?
Where is Halozyme Therapeutics located?
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company’s products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; and Centre for the AIDS Programme of Research in South Africa. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
NASDAQ
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally.
Environmental, Social, and Governance Rating
A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.
Business Summary
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
When will Halozyme Therapeutics release its earnings?
A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.
How much does Halozyme Therapeutics make?
Halozyme Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021. View our earnings forecast for Halozyme Therapeutics.
